Modifiable Variables in Parkinsonism Study

Migration, Crosslink

📖

Modifiable Variables in Parkinsonism Study

active

wiki page Created: 2026-04-02T07:19:03 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-clinical-trials-modifiable-variable

📖 Wiki Page

clinical1439 wordssynced 2026-04-02

Overview

flowchart TD clinical_trials_modifiable_var["Modifiable Variables in Parkinsonism Study"] style clinical_trials_modifiable_var fill:#4fc3f7,stroke:#333,color:#000 clinical_trials_modi_0["Study Details"] clinical_trials_modifiable_var -->|"includes"| clinical_trials_modi_0 style clinical_trials_modi_0 fill:#81c784,stroke:#333,color:#000 clinical_trials_modi_1["Risk Factors Overview"] clinical_trials_modifiable_var -->|"includes"| clinical_trials_modi_1 style clinical_trials_modi_1 fill:#ef5350,stroke:#333,color:#000 clinical_trials_modi_2["Non-Modifiable Factors"] clinical_trials_modifiable_var -->|"includes"| clinical_trials_modi_2 style clinical_trials_modi_2 fill:#ffd54f,stroke:#333,color:#000 clinical_trials_modi_3["Potentially Modifiable Factors"] clinical_trials_modifiable_var -->|"includes"| clinical_trials_modi_3 style clinical_trials_modi_3 fill:#ce93d8,stroke:#333,color:#000 clinical_trials_modi_4["Potentially Protective Factors"] clinical_trials_modifiable_var -->|"includes"| clinical_trials_modi_4 style clinical_trials_modi_4 fill:#4fc3f7,stroke:#333,color:#000 clinical_trials_modi_5["Study Objectives"] clinical_trials_modifiable_var -->|"includes"| clinical_trials_modi_5 style clinical_trials_modi_5 fill:#81c784,stroke:#333,color:#000

...

Overview

Mermaid diagram (expand to render)

This observational study investigates modifiable lifestyle and environmental factors that may influence the risk, progression, and severity of [Parkinson's disease](/diseases/parkinsons-disease) and related disorders, including [Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy), [Multiple System Atrophy](/diseases/multiple-system-atrophy), and [Corticobasal Degeneration](/diseases/corticobasal-degeneration)[@kalia_2015].

While genetic factors contribute to Parkinson's disease risk, the majority of cases are sporadic, suggesting that environmental and lifestyle factors play a significant role["@noyce_2012"]. This study aims to characterize these modifiable factors to identify potential prevention strategies and disease-modifying interventions["@foltynie_2021"].

[Parkinson's disease](/diseases/parkinsons-disease) affects approximately 1-2% of the population over 65 years, rising to 3-5% in those over 85[@jankovic_2020]. The global prevalence is estimated at over 10 million people. Key epidemiological features include:

Slight male predominance (1.5:1 ratio)
Typical onset between 50-70 years
Increasing incidence with age
Geographic variation in prevalence

Study Details

| Parameter | Value |
|-----------|-------|
| NCT Number | NCT02194816 |
| Status | Recruiting |
| Study Type | Observational |
| Conditions | Parkinson's Disease, PSP, MSA, CBS |
| Sites | United States (multiple centers) |
| Enrollment | Target: Multiple participants |
| Start Date | 2014 |

Risk Factors Overview

Multiple factors influence Parkinson's disease risk[@bellou_2016]:

Non-Modifiable Factors

Age (strongest risk factor)
Male sex
Genetic susceptibility (family history, specific genes)
Ethnic background

Potentially Modifiable Factors

Pesticide exposure
Head trauma
Dairy product consumption
Psychological stress

Potentially Protective Factors

Caffeine consumption
Physical activity
Smoking (controversial - nicotine vs. confounding)
Alcohol consumption (moderate)
Anti-inflammatory drug use

Study Objectives

Primary Objectives

Characterize Lifestyle Factors

Document caffeine and nicotine use
Assess physical activity levels
Evaluate dietary patterns
Record medication history

Assess Environmental Exposures

Occupational history
Pesticide exposure assessment
Living environment
Water source

Correlate with Clinical Outcomes

Disease severity measures
Progression rates
Motor and non-motor symptoms
Treatment response

Identify Intervention Targets

Risk factor quantification
Protective factor validation
Target population identification

Secondary Objectives

Evaluate gender-specific effects
Assess age-of-onset relationships
Characterize gene-environment interactions
Develop risk prediction models

Assessment Areas

Caffeine and Nicotine Use

Epidemiological studies consistently show inverse associations between caffeine consumption and Parkinson's disease risk[@hernandez_2019]:

Coffee consumption: 30-60% risk reduction in meta-analyses
Tea consumption: similar inverse association
Caffeine dose-response relationship
Potential neuroprotective mechanisms:
Adenosine A2A receptor antagonism
Antioxidant effects
Anti-inflammatory properties

Nicotine has also been studied extensively[@polman_2012]:

Historical smoking association with reduced PD risk
Contributes to inverse association in some studies
Confounded by lifestyle factors
Nicotinic receptor modulation as therapeutic target

Physical Activity

Exercise and physical activity have emerged as potentially disease-modifying interventions[@chen_2019]:

Regular exercise associated with 30-50% risk reduction
Mechanisms include:
Neurotrophic factor upregulation
Mitochondrial function improvement
Neuroinflammation reduction
Alpha-synuclein clearance enhancement
Recommended exercise types:
Aerobic exercise
Balance training
Resistance training
Dance-based therapies

Dietary Patterns

Nutritional factors influence Parkinson's disease risk[@gao_2011]:

Potentially Protective:
Mediterranean diet
Omega-3 fatty acids
Fruits and vegetables
Antioxidant-rich foods
Potentially Risk-Increasing:
High dairy intake
Saturated fats
Processed foods
Mediterranean Diet Evidence[@delenord_2019]:
Associated with lower PD risk
Benefits from anti-inflammatory effects
Rich in polyphenols and antioxidants

Medication History

Certain medications may modify Parkinson's disease risk:

Statins: Conflicting evidence - some studies show reduced risk[@logroscino_2018]
NSAIDs: Mixed results for anti-inflammatory effects
Beta-blockers: Theoretical benefits via adrenergic modulation
Calcium channel blockers: Some protective signals

Occupational Exposures

Pesticide and chemical exposures represent significant risk factors[@ascherio_2016]:

Pesticide Exposure

Herbicides: Paraquat, rotenone
Insecticides: Organophosphates, pyrethroids
Fungicides: Maneb, mancozeb

Mechanisms of neurotoxicity[@tanner_2011]:

Mitochondrial complex I inhibition
Oxidative stress induction
Alpha-synuclein aggregation promotion
Dopaminergic neuron selectivity

Occupations at Risk

Agricultural workers
Pesticide applicators
Farm managers
Greenhouse workers

Protective Measures:

Personal protective equipment
Engineering controls
Safe handling practices
Rotation of duties

Clinical Measures

Movement Disorder Assessments

MDS-UPDRS (Movement Disorder Society-Unified Parkinson's Disease Rating Scale)

The gold-standard assessment tool:

Part I: Non-motor experiences of daily living
Part II: Motor experiences of daily living
Part III: Motor examination
Part IV: Motor complications

Hoehn and Yahr Staging

Stage 0: No signs of disease
Stage 1: Unilateral involvement
Stage 1.5: Unilateral and axial involvement
Stage 2: Bilateral involvement without impairment
Stage 2.5: Mild bilateral disease with recovery on pull test
Stage 3: Mild to moderate disease, some postural instability
Stage 4: Severe disability, still able to walk/stand
Stage 5: Wheelchair-bound or bedridden

PSP Rating Scale (PSPRS)

For PSP and related disorders:

Gait and mobility
Ocular motor dysfunction
Dysphagia
Cortical dysfunction
Axonal rigidity

Non-Motor Assessments

Cognitive Testing

Montreal Cognitive Assessment (MoCA)
Trail Making Test
Word fluency
Memory recall

Psychiatric Evaluation

Beck Depression Inventory
State-Trait Anxiety Inventory
apathy assessment

Sleep Assessment

REM sleep behavior disorder questionnaire
Epworth Sleepiness Scale
Polysomnography when indicated

Quality of Life Measures

Parkinson's Disease Questionnaire-39 (PDQ-39)
SF-36 Health Survey
Caregiver burden scales

Eligibility Criteria

Inclusion Criteria

Diagnosis of Parkinsonian Syndrome

Clinical diagnosis of Parkinson's disease, PSP, MSA, or CBS
UK Brain Bank criteria or equivalent
Progressive disease course

Age Requirements

Age 40-90 years
Disease duration any stage

Ability to Participate

Able to complete questionnaires
Available for study visits
Informed consent obtained

Exclusion Criteria

Secondary Parkinsonism

Drug-induced parkinsonism
Vascular parkinsonism
Normal pressure hydrocephalus

Medical Contraindications

Unable to complete study procedures
Terminal illness
Severe cognitive impairment preventing consent

Study Design

Cross-Sectional Components

Baseline lifestyle questionnaire
Environmental exposure assessment
Clinical phenotype characterization

Longitudinal Components

Annual follow-up assessments
Disease progression tracking
Change in exposure status documentation

Data Collection Methods

Interviewer-administered questionnaires
Self-administered diaries
Medical record review
Biological sample collection

Understanding Disease Mechanisms

This study contributes to understanding how environmental factors influence neurodegenerative processes:

Gene-Environment Interactions

How genetic susceptibility modifies environmental risk
Epigenetic modifications from exposures

Mechanistic Insights

Identification of environmental triggers
Understanding of protective mechanisms

Prevention Strategies

Identifying modifiable risk factors enables development of prevention strategies[@kieburtz_2019]:

Primary Prevention

Reducing pesticide exposure
Promoting physical activity
Dietary modifications

Secondary Prevention (Early Intervention)

Early identification of prodromal markers
Intervention before significant neurodegeneration

Disease Modification

Targeting mechanisms influenced by lifestyle
Complementing pharmacological approaches

Clinical Trial Implications

Risk Factor Modification: Lifestyle interventions as adjuncts to pharmacological treatments
Endpoint Selection: Environmental factors affecting progression
Patient Stratification: Exposure-based phenotyping
Neuroprotective Trials: Environmental modifiers as targets

Limitations and Challenges

Observational Design

Cannot establish causality
Potential for confounding
Recall bias in exposure assessment

Exposure Assessment

Latency between exposure and disease
Difficulty quantifying exposures
Recall limitations

Generalizability

Geographic specificity
Referral bias
Cohort representativeness

Parkinson's Disease Pathogenesis

[Alpha-synuclein Aggregation](/mechanisms/alpha-synuclein-aggregation)
[Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction)
[Neuroinflammation](/mechanisms/neuroinflammation)
[Oxidative Stress](/mechanisms/oxidative-stress)

Protective Mechanisms

[Exercise-Induced Neuroprotection](/mechanisms/exercise-neuroprotection)
[Caffeine Neuroprotection](/mechanisms/caffeine-neuroprotection)
[Antioxidant Defense](/mechanisms/antioxidant-defense)

Risk Factors

[Pesticide-Induced Neurodegeneration](/mechanisms/pesticide-neurotoxicity)
[Traumatic Brain Injury](/mechanisms/tbi-neurodegeneration)

External Links

[ClinicalTrials.gov NCT02194816](https://clinicaltrials.gov/study/NCT02194816)
[Michael J. Fox Foundation](https://www.michaeljfox.org)
[Parkinson's Foundation](https://www.parkinson.org)

References

[ClinicalTrials.gov NCT02194816](https://clinicaltrials.gov/study/NCT02194816)[@nct02194816]

[Ascherio et al., Pesticide exposure and risk of Parkinson disease (2016)](https://pubmed.ncbi.nlm.nih.gov/27481211/)[@ascherio_2016]

[Hernandez et al., Caffeine and Parkinson's disease (2019)](https://pubmed.ncbi.nlm.nih.gov/30666636/)[@hernandez_2019]

[Polman et al., Smoking and Parkinson's disease (2012)](https://pubmed.ncbi.nlm.nih.gov/22729864/)[@polman_2012]

[Chen et al., Physical activity and Parkinson's disease (2019)](https://pubmed.ncbi.nlm.nih.gov/31721955/)[@chen_2019]

[Gao et al., Diet and Parkinson's disease (2011)](https://pubmed.ncbi.nlm.nih.gov/21671250/)[@gao_2011]

[Kieburtz et al., Neuroprotection in Parkinson's disease (2019)](https://pubmed.ncbi.nlm.nih.gov/31286842/)[@kieburtz_2019]

[Noyce et al., Meta-analysis of Parkinson's disease risk factors (2012)](https://pubmed.ncbi.nlm.nih.gov/22653198/)[@noyce_2012]

[Bellou et al., Environmental risk factors for Parkinson's disease (2016)](https://pubmed.ncbi.nlm.nih.gov/26896655/)[@bellou_2016]

[Kalia et al., Parkinson's disease: clinical practice (2015)](https://pubmed.ncbi.nlm.nih.gov/25904018/)[@kalia_2015]

[Tanner et al., Rotenone and Parkinson's disease (2011)](https://pubmed.ncbi.nlm.nih.gov/21398046/)[@tanner_2011]

[Jankovic et al., Parkinson's disease: current challenges (2020)](https://pubmed.ncbi.nlm.nih.gov/32676629/)[@jankovic_2020]

[Postema et al., Gait and balance in PD (2019)](https://pubmed.ncbi.nlm.nih.gov/31029513/)[@postema_2019]

[Williams et al., Occupational pesticide exposure (2020)](https://pubmed.ncbi.nlm.nih.gov/32940602/)[@williams_2020]

[Haaxma et al., Gender differences in Parkinson's disease (2007)](https://pubmed.ncbi.nlm.nih.gov/17437064/)[@haaxma_2007]

[Foltynie et al., Modifiable factors in Parkinson's disease (2021)](https://pubmed.ncbi.nlm.nih.gov/34717598/)[@foltynie_2021]

[Pfeiffer, Mitochondrial dysfunction in Parkinson's disease (2013)](https://pubmed.ncbi.nlm.nih.gov/23978890/)[@pfeiffer_2013]

[Pavese, Occupational epidemiology and Parkinson's disease (2010)](https://pubmed.ncbi.nlm.nih.gov/20483818/)[@pavese_2010]

[Delenord et al., Mediterranean diet and Parkinson's disease (2019)](https://pubmed.ncbi.nlm.nih.gov/30859967/)[@delenord_2019]

[Logroscino et al., Statins and Parkinson's disease (2018)](https://pubmed.ncbi.nlm.nih.gov/30367306/)[@logroscino_2018]

📖 View canonical wiki page →

Related Entities

clinical-trials-modifiable-variables-parkinsonism-nct02194816

▸Metadataorigin_type: v1_polymorphic_backfill

slug	clinical-trials-modifiable-variables-parkinsonism-nct02194816
kg_node_id	None
entity_type	clinical
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-b9166c250e1b
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'clinical-trials-modifiable-variables-parkinsonism-nct02194816'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

65%

Debates

0

Incoming

13

Outgoing

21

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Modifiable Variables in Parkinsonism Study

Overview

Overview

Study Details

Risk Factors Overview

Non-Modifiable Factors

Potentially Modifiable Factors

Potentially Protective Factors

Study Objectives

Primary Objectives

Secondary Objectives

Assessment Areas

Caffeine and Nicotine Use

Physical Activity

Dietary Patterns

Medication History

Occupational Exposures

Pesticide Exposure

Occupations at Risk

Clinical Measures

Movement Disorder Assessments

MDS-UPDRS (Movement Disorder Society-Unified Parkinson's Disease Rating Scale)

Hoehn and Yahr Staging

PSP Rating Scale (PSPRS)

Non-Motor Assessments

Cognitive Testing

Psychiatric Evaluation

Sleep Assessment

Quality of Life Measures

Eligibility Criteria

Inclusion Criteria

Exclusion Criteria

Study Design

Cross-Sectional Components

Longitudinal Components

Data Collection Methods

Understanding Disease Mechanisms

Prevention Strategies

Clinical Trial Implications

Limitations and Challenges

Observational Design

Exposure Assessment

Generalizability

Related Mechanisms and Pathways

Parkinson's Disease Pathogenesis

Protective Mechanisms

Risk Factors

See Also

External Links

References

💬 Discussion